Summary of Study ST003031

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001884. The data can be accessed directly via it's Project DOI: 10.21228/M8672X This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST003031
Study Title	Early time-restricted eating improves markers of cardiometabolic health but has no impact on nutrient absorption in healthy adults
Study Type	Randomized Controlled Trial
Study Summary	Metabolomic analysis performed on 88 human plasma samples collected from 16 participants that received 2 treatments with 3 time points each. Samples were analyzed by UPLC-MS using a Waters Acquity UPLC and detected on a 4000 QTrap by multiple reaction monitoring (MRM) with negative mode electrospray ionization.
Institute	California Polytechnic State University, San Luis Obispo
Last Name	La Frano
First Name	Michael
Address	Cal Poly State University 1 Grand Avenue San Luis Obispo, CA 93407
Email	mlafrano@calpoly.edu
Phone	(805) 756-6233
Submit Date	2023-12-15
Num Groups	2
Raw Data Available	Yes
Raw Data File Type(s)	mzML
Analysis Type Detail	LC-MS
Release Date	2024-01-23
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR001884
Project DOI:	doi: 10.21228/M8672X
Project Title:	Early time-restricted eating improves markers of cardiometabolic health but has no impact on nutrient absorption in healthy adults
Project Type:	Randomized Controlled Trial
Project Summary:	Early time-restricted eating (eTRE) improves aspects of cardiometabolic health. Although the circadian system appears to regulate nutrient absorption, little is known about the effects of eTRE on intestinal absorption. In this randomized crossover trial, 16 healthy adults follow a controlled, weight-maintenance diet for 9 days consuming all calories between 0800 and 1400 (eTRE schedule) or 0800 and 2000 (control schedule). We measure the energy content of the diet, stool, and urine with bomb calorimetry and calculate intestinal energy absorption. The eTRE schedule is more effective than the control eating schedule for improving markers of cardiometabolic health, including 24-h mean glucose concentrations and glycemic variability, assessed as the mean amplitude of glycemic excursions. However, eTRE has no effect on intestinal energy and macronutrient absorption, gastrointestinal transit time, colonic hydrogen gas production, or stool microbial composition, suggesting eTRE does not impact gastrointestinal function.
Institute:	Pennington Biomedical Research Center
Department:	Clinical Sciences
Last Name:	Berryman
First Name:	Claire
Address:	6400 Perkins Road, Baton Rouge, LA 70808
Email:	claire.berryman@pbrc.edu
Phone:	(225) 763-3010

Subject:

Subject ID:	SU003145
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Species Group:	Mammals

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id	local_sample_id	Treatment Group	Timepoint
SA328117	DIG012 DP1.Fasting plasma	DP1	Fasting
SA328118	DIG011 DP1.Fasting plasma	DP1	Fasting
SA328119	DIG009 DP1.Fasting plasma	DP1	Fasting
SA328120	DIG014 DP1.Fasting plasma	DP1	Fasting
SA328121	DIG010 DP1.Fasting plasma	DP1	Fasting
SA328122	DIG017 DP1.Fasting plasma	DP1	Fasting
SA328123	DIG020 DP1.Fasting plasma	DP1	Fasting
SA328124	DIG019 DP1.Fasting plasma	DP1	Fasting
SA328125	DIG018 DP1.Fasting plasma	DP1	Fasting
SA328126	DIG008 DP1.Fasting plasma	DP1	Fasting
SA328127	DIG016 DP1.Fasting plasma	DP1	Fasting
SA328128	DIG013 DP1.Fasting plasma	DP1	Fasting
SA328129	DIG006 DP1.Fasting plasma	DP1	Fasting
SA328130	DIG007 DP1.Fasting plasma	DP1	Fasting
SA328131	DIG016 DP1.Hour 2 plasma	DP1	Hour 2
SA328132	DIG020 DP1.Hour 2 plasma	DP1	Hour 2
SA328133	DIG017 DP1.Hour 2 plasma	DP1	Hour 2
SA328134	DIG012 DP1.Hour 2 plasma	DP1	Hour 2
SA328135	DIG011 DP1.Hour 2 plasma	DP1	Hour 2
SA328136	DIG010 DP1.Hour 2 plasma	DP1	Hour 2
SA328137	DIG019 DP1.Hour 2 plasma	DP1	Hour 2
SA328138	DIG009 DP1.Hour 2 plasma	DP1	Hour 2
SA328139	DIG013 DP1.Hour 2 plasma	DP1	Hour 2
SA328140	DIG018 DP1.Hour 2 plasma	DP1	Hour 2
SA328141	DIG007 DP1.Hour 2 plasma	DP1	Hour 2
SA328142	DIG014 DP1.Hour 2 plasma	DP1	Hour 2
SA328143	DIG008 DP1.Hour 2 plasma	DP1	Hour 2
SA328144	DIG006 DP1.Hour 2 plasma	DP1	Hour 2
SA328145	DIG017 DP1.Hour 4 plasma	DP1	Hour 4
SA328146	DIG014 DP1.Hour 4 plasma	DP1	Hour 4
SA328147	DIG011 DP1.Hour 4 plasma	DP1	Hour 4
SA328148	DIG012 DP1.Hour 4 plasma	DP1	Hour 4
SA328149	DIG019 DP1.Hour 4 plasma	DP1	Hour 4
SA328150	DIG018 DP1.Hour 4 plasma	DP1	Hour 4
SA328151	DIG010 DP1.Hour 4 plasma	DP1	Hour 4
SA328152	DIG009 DP1.Hour 4 plasma	DP1	Hour 4
SA328153	DIG016 DP1.Hour 4 plasma	DP1	Hour 4
SA328154	DIG008 DP1.Hour 4 plasma	DP1	Hour 4
SA328155	DIG020 DP1.Hour 4 plasma	DP1	Hour 4
SA328156	DIG006 DP1.Hour 4 plasma	DP1	Hour 4
SA328157	DIG013 DP1.Hour 4 plasma	DP1	Hour 4
SA328158	DIG007 DP1.Hour 4 plasma	DP1	Hour 4
SA328159	DIG015 DP2.Fasting plasma	DP2	Fasting
SA328160	DIG017 DP2.Fasting plasma	DP2	Fasting
SA328161	DIG016 DP2.Fasting plasma	DP2	Fasting
SA328162	DIG014 DP2.Fasting plasma	DP2	Fasting
SA328163	DIG007 DP2.Fasting plasma	DP2	Fasting
SA328164	DIG010 DP2.Fasting plasma	DP2	Fasting
SA328165	DIG006 DP2.Fasting plasma	DP2	Fasting
SA328166	DIG020 DP2.Fasting plasma	DP2	Fasting
SA328167	DIG009 DP2.Fasting plasma	DP2	Fasting
SA328168	DIG008 DP2.Fasting plasma	DP2	Fasting
SA328169	DIG018 DP2.Fasting plasma	DP2	Fasting
SA328170	DIG011 DP2.Fasting plasma	DP2	Fasting
SA328171	DIG013 DP2.Fasting plasma	DP2	Fasting
SA328172	DIG019 DP2.Fasting plasma	DP2	Fasting
SA328173	DIG005 DP2.Fasting plasma	DP2	Fasting
SA328174	DIG012 DP2.Fasting plasma	DP2	Fasting
SA328175	DIG006 DP2.Hour 2 plasma	DP2	Hour 2
SA328176	DIG020 DP2.Hour 2 plasma	DP2	Hour 2
SA328177	DIG018 DP2.Hour 2 plasma	DP2	Hour 2
SA328178	DIG019 DP2.Hour 2 plasma	DP2	Hour 2
SA328179	DIG017 DP2.Hour 2 plasma	DP2	Hour 2
SA328180	DIG007 DP2.Hour 2 plasma	DP2	Hour 2
SA328181	DIG010 DP2.Hour 2 plasma	DP2	Hour 2
SA328182	DIG016 DP2.Hour 2 plasma	DP2	Hour 2
SA328183	DIG011 DP2.Hour 2 plasma	DP2	Hour 2
SA328184	DIG012 DP2.Hour 2 plasma	DP2	Hour 2
SA328185	DIG013 DP2.Hour 2 plasma	DP2	Hour 2
SA328186	DIG014 DP2.Hour 2 plasma	DP2	Hour 2
SA328187	DIG015 DP2.Hour 2 plasma	DP2	Hour 2
SA328188	DIG009 DP2.Hour 2 plasma	DP2	Hour 2
SA328189	DIG008 DP2.Hour 2 plasma	DP2	Hour 2
SA328190	DIG007 DP2.Hour 4 plasma	DP2	Hour 4
SA328191	DIG009 DP2.Hour 4 plasma	DP2	Hour 4
SA328192	DIG010 DP2.Hour 4 plasma	DP2	Hour 4
SA328193	DIG020 DP2.Hour 4 plasma	DP2	Hour 4
SA328194	DIG011 DP2.Hour 4 plasma	DP2	Hour 4
SA328195	DIG019 DP2.Hour 4 plasma	DP2	Hour 4
SA328196	DIG015 DP2.Hour 4 plasma	DP2	Hour 4
SA328197	DIG017 DP2.Hour 4 plasma	DP2	Hour 4
SA328198	DIG016 DP2.Hour 4 plasma	DP2	Hour 4
SA328199	DIG014 DP2.Hour 4 plasma	DP2	Hour 4
SA328200	DIG008 DP2.Hour 4 plasma	DP2	Hour 4
SA328201	DIG013 DP2.Hour 4 plasma	DP2	Hour 4
SA328202	DIG006 DP2.Hour 4 plasma	DP2	Hour 4
SA328203	DIG018 DP2.Hour 4 plasma	DP2	Hour 4
SA328204	DIG012 DP2.Hour 4 plasma	DP2	Hour 4

Showing results 1 to 88 of 88

Showing results 1 to 88 of 88

Collection:

Collection ID:	CO003138
Collection Summary:	Whole blood was collected from the antecubital vein while participants were fasted, and 2-and 4-h after a mixed meal challenge in EDTA vacutainer tubes (BD Vacutainer, New Jersey, USA).
Sample Type:	Blood (plasma)

Treatment:

Treatment ID:	TR003154
Treatment Summary:	This study was approved by the Florida State University Institutional Review Board and registered on clinicaltrials.gov (NCT04877262). Healthy, adults who were normal-weight (BMI:18.5-24.9 kg/m2) or overweight (BMI: 25-29.9 kg/m2) and 23-42 y, were recruited from the greater Tallahassee, Florida area between December 2021 and May 2022 and provided informed consent prior to participating. Potential participants were excluded if they had any disease or condition known to interfere with metabolism or normal gastrointestinal function (diabetes, cardiovascular disease, kidney disease, prior bariatric surgery, suspected or known fistulas, gastrointestinal obstruction, gastrointestinal disease, colonoscopy within 3 months of the study, alcoholism, substance abuse disorders); irregular menstrual cycle in the past 6 months; weight fluctuations greater that 5% during the previous 6 months; antibiotic use within 3 months of participation; allergies or intolerances to foods included in the controlled diet; habitual use of laxatives, stool softeners, or anti-diarrheal medications (≥ 1x/week); whole-gut transit time >72 h; or were pregnant or lactating. Participants followed an early time-restricted eating (eTRE) schedule (i.e., all meals consumed in a 6-h window between 0800 and 1400) and a control eating schedule (i.e., all meals consumed in a 12-h window between 0800 and 2000) for 9-d each in randomized order. On day 6 of each study period, participants arrived in the morning to the laboratory for a mixed-meal tolerance test (MMTT). Participants spent 6 hours in the laboratory to measure fasting (0h) and postprandial (2h and 4h) plasma metabolite concentrations in response to the MMTT. Whole blood was collected in EDTA vacutainer tubes (BD Vacutainer, Franklin Lakes, New Jersey, USA) and centrifuged at 3000 RPM for 15 minutes at 4°C before aliquots were frozen at -80°C until analysis.

Treatment ID:

TR003154

Treatment Summary:

This study was approved by the Florida State University Institutional Review Board and registered on clinicaltrials.gov (NCT04877262). Healthy, adults who were normal-weight (BMI:18.5-24.9 kg/m2) or overweight (BMI: 25-29.9 kg/m2) and 23-42 y, were recruited from the greater Tallahassee, Florida area between December 2021 and May 2022 and provided informed consent prior to participating. Potential participants were excluded if they had any disease or condition known to interfere with metabolism or normal gastrointestinal function (diabetes, cardiovascular disease, kidney disease, prior bariatric surgery, suspected or known fistulas, gastrointestinal obstruction, gastrointestinal disease, colonoscopy within 3 months of the study, alcoholism, substance abuse disorders); irregular menstrual cycle in the past 6 months; weight fluctuations greater that 5% during the previous 6 months; antibiotic use within 3 months of participation; allergies or intolerances to foods included in the controlled diet; habitual use of laxatives, stool softeners, or anti-diarrheal medications (≥ 1x/week); whole-gut transit time >72 h; or were pregnant or lactating. Participants followed an early time-restricted eating (eTRE) schedule (i.e., all meals consumed in a 6-h window between 0800 and 1400) and a control eating schedule (i.e., all meals consumed in a 12-h window between 0800 and 2000) for 9-d each in randomized order. On day 6 of each study period, participants arrived in the morning to the laboratory for a mixed-meal tolerance test (MMTT). Participants spent 6 hours in the laboratory to measure fasting (0h) and postprandial (2h and 4h) plasma metabolite concentrations in response to the MMTT. Whole blood was collected in EDTA vacutainer tubes (BD Vacutainer, Franklin Lakes, New Jersey, USA) and centrifuged at 3000 RPM for 15 minutes at 4°C before aliquots were frozen at -80°C until analysis.

Sample Preparation:

Sampleprep ID:	SP003151
Sampleprep Summary:	Plasma (25 μL) was added to 1.5 mL Eppendorf tubes prior to the addition of 10 μL of 1 μM internal standard solution. Next, 750 μL chilled methanol was added and samples were vortexed 30 s before centrifugation at 15,000 × G for 10 min. Subsequently, the supernatant was collected and added to 1.5 mL high performance liquid chromatography (HPLC) amber glass vials, dried, and reconstituted in 100 μL 3:1 acetonitrile: methanol containing 1-cyclohexyl-ureido, 3-dodecanoic acid (CUDA; Sigma-Aldrich, St. Louis, MO, USA) solution. The solution was vortexed 30 s, transferred to microfilter tubes, and centrifuged at 10,000 × G for 3 min prior to transfer to a HPLC vial.
Sampleprep Protocol Filename:	La_Frano_Lab_Methods_eTRE_v2.pdf

Combined analysis:

Analysis ID	AN004968
Analysis type	MS
Chromatography type	HILIC
Chromatography system	Waters Acquity I-Class
Column	Phenomenex Luna NH2 (150 x 2mm,3um)
MS Type	ESI
MS instrument type	Triple quadrupole
MS instrument name	ABI Sciex 4000 QTrap
Ion Mode	NEGATIVE
Units	Peak area

Chromatography:

Chromatography ID:	CH003750
Methods Filename:	La_Frano_Lab_Methods_eTRE_v2.pdf
Instrument Name:	Waters Acquity I-Class
Column Name:	Phenomenex Luna NH2 (150 x 2mm,3um)
Column Temperature:	30
Flow Gradient:	0 min 90%B, 10 min 5%B, 11 min 5%B, 13 min 90%B, 15 min 90%B
Flow Rate:	0.3 ml/min
Solvent A:	100% water with 20 mM ammonium acetate, 20 mM ammonium hydroxide
Solvent B:	10 mM ammonium hydroxide in 75:25 % v/v (volume %) acetonitrile/methanol
Chromatography Type:	HILIC

MS:

MS ID:	MS004708
Analysis ID:	AN004968
Instrument Name:	ABI Sciex 4000 QTrap
Instrument Type:	Triple quadrupole
MS Type:	ESI
MS Comments:	Acquisition software AB Sciex Analyst and quantitation software Sciex MultiQuant. Metabolites detected using multiple reaction monitoring (MRM).
Ion Mode:	NEGATIVE
Analysis Protocol File:	La_Frano_Lab_Methods_eTRE_v2.pdf